Publication date: Aug 12, 2024
Nipah virus infection, one of the top priority diseases recognized by the World Health Organization, underscores the urgent need to develop effective countermeasures against potential epidemics and pandemics. Here, we identify a fully human single-domain antibody that targets a highly conserved cryptic epitope situated at the dimeric interface of the Nipah virus G protein (receptor binding protein, RBP), as elucidated through structures by high-resolution cryo-electron microscopy (cryo-EM). This unique binding mode disrupts the tetramerization of the G protein, consequently obstructing the activation of the F protein and inhibiting viral membrane fusion. Furthermore, our investigations reveal that this compact antibody displays enhanced permeability across the blood-brain barrier (BBB) and demonstrates superior efficacy in eliminating pseudovirus within the brain in a murine model of Nipah virus infection, particularly compared to the well-characterized antibody m102. 4 in an IgG1 format. Consequently, this single-domain antibody holds promise as a therapeutic candidate to prevent Nipah virus infections and has potential implications for vaccine development.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Nipah virus infection |
disease | MESH | virus infection |
disease | MESH | encephalitis |
disease | MESH | Infection |
disease | MESH | Lung Inflammation |
disease | MESH | emergency |
drug | DRUGBANK | Amino acids |
drug | DRUGBANK | Coenzyme M |
disease | MESH | dissociation |
drug | DRUGBANK | Glycine |
disease | MESH | influenza |
drug | DRUGBANK | Serine |
drug | DRUGBANK | Sodium lauryl sulfate |
drug | DRUGBANK | Biotin |
drug | DRUGBANK | Isopropyl beta-D-thiogalactopyranoside |
drug | DRUGBANK | Histidine |
drug | DRUGBANK | Sodium acetate |